The Albany Gazette - enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

NYSE - LSE

RBGPF	1.65%	83.78	$
SCS	0.12%	16.14	$
RYCEF	-0.41%	16.88	$
CMSC	0.04%	23.71	$
AZN	-0.68%	92.59	$
GSK	1.11%	50.66	$
CMSD	0.16%	24.09	$
BTI	0.1%	60.22	$
RELX	-3.35%	36.17	$
NGG	0.46%	85.07	$
BCE	0.86%	25.49	$
BCC	-0.68%	80.3	$
RIO	1.85%	95.13	$
JRI	-0.39%	12.94	$
VOD	0.95%	14.71	$
BP	0.89%	38.04	$

enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

TECHNOLOGY 22.07.2025

enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

- Video webcast now available on-demand

Text size:

IRVINE, CA / ACCESS Newswire / July 22, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Rob Berman, CEO of enVVeno, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.

As part of the segment, Mr. Berman dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's products in development.

The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page of the enVVeno website, envveno.com.

About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insuffihttps://virtualinvestorco.com/summer-spotlight/cy (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.

INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
[email protected]
(908) 824-0775

MEDIA CONTACT:
Glenn Silver, FINN Partners
[email protected]
(973) 818-8198

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

(A.Thompson--TAG)

Featured

Apple earnings soar as China iPhone sales surge

Apple on Thursday said it saw record-high earnings in the final three months of last year, with iPhone sales surging in greater China.

Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.

New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programsGelrinC is set to transform cartilage repair market with off-the-shelf regenerative products

GameSquare's Stream Hatchet Publishes Annual 2025 Live Streaming Trends Report

Global live streaming viewership grew 6% year-over-year to 36.4B hours watched during 2025, nearly matching 2021's pandemic-era peak

Dynamite Blockchain Announces Recent Milestones in Its MOT Token Holding

MOT Achieves New All-Time High and Expands Market Visibility